The primary objective of the Informatics Core is to contribute to the science and operation of the Program Project by providing the informatics infrastructure and specialized technical expertise required to support the complex data integration and analysis needs of the grant. The scientific goals of the Projects are highly integrated and will require the analysis of shared data in an iterafive fashion throughout the five years. The Core is split into two teams, each with its own faculty director. The University of Minnesota team (MN Team) is led by Dr. Sarah Cooley, Director of the Masonic Cancer Center Medical Informafics Shared Resources. The MN team is responsible for the development and maintenance of database applications to collect, integrate and report research data generated by the projects for subsequent analysis. In addition they will support and customize the clinical trials management applicafion to meet the research and regulatory data requirements for the complex (phase I, IND, mulfi-center) trials in Projects 2 and 3. The sharing of research samples will be coordinated through this Core with a customized sample inventory management tool. Lasfiy, this team will develop and support the SOPs for data quality, data integrity, and data sharing, in compliance with HIPAA and caBIG principles. This team has collaborated in the development of the scientific plan by developing data collecfion and management plans specific to each aim, and will remain acfively involved with each Project and Core throughout the life of this grant to monitor data quality and prepare datasets for analysis. The second team, led by Dr. Steven GE Marsh from the Anthony Nolan Trust, is responsible for the unique and specialized tools required for the storage, sharing and analysis of immunogenefic KIR data. The IPD-KIR database was established during the first cycle of this POI, and has proved a valuable resource for data analysis. They will confinue to produce software tools to calculate KIR gene frequencies, allele frequencies and to esfimate haplotypes and their frequencies at allelic level, define new alleles discovered by the Projects and Core D, and provide data crucial for the development of the high-resolufion typing strategy to be employed in Project 1 (Parham) and Core D. Addifionally they will provide sequence alignment tools for the analysis and visualizafion of the intergenic regions between KIR genes (Project 2). To support the clinical trials, they will develop a simple tool to predict the KIR haplotypes in any given individual, and indicate their content in terms of the centromeric and telomeric portions of the haplotype. The scientific expertise provided by this team will be invaluable to analyze and interpret immunogenetic data.

Public Health Relevance

The Program Project grant, which includes three clinical trials and multiple laboratory-based research studies, will generate significant amounts of complex data from mulfiple sites, all of which must be integrated for definifive analysis. This Core contains Faculty and staff at the University of Minnesota and from the Anthony Nolan Trust to develop and support the requisite informatics tools to support the clinical trials and basic research aims.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA111412-08
Application #
8380850
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
8
Fiscal Year
2012
Total Cost
$189,776
Indirect Cost
$53,785
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Williams, Robin L; Cooley, Sarah; Bachanova, Veronika et al. (2017) Recipient T Cell Exhaustion and Successful Adoptive Transfer of Haploidentical Natural Killer Cells. Biol Blood Marrow Transplant :
Robinson, James; Guethlein, Lisbeth A; Cereb, Nezih et al. (2017) Distinguishing functional polymorphism from random variation in the sequences of >10,000 HLA-A, -B and -C alleles. PLoS Genet 13:e1006862
Schmohl, Jörg U; Felices, Martin; Oh, Felix et al. (2017) Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity. Cancer Res Treat 49:1140-1152
Cichocki, Frank; Valamehr, Bahram; Bjordahl, Ryan et al. (2017) GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity. Cancer Res 77:5664-5675
Davis, Zachary B; Vallera, Daniel A; Miller, Jeffrey S et al. (2017) Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol 31:64-75
Hoff, Gretchen A; Fischer, Johannes C; Hsu, Katharine et al. (2017) Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes. Biol Blood Marrow Transplant 23:153-160
Boyiadzis, Michael; Bishop, Michael R; Abonour, Rafat et al. (2016) The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer 4:90
Bachanova, Veronika; Weisdorf, Daniel J; Wang, Tao et al. (2016) Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation. Biol Blood Marrow Transplant 22:1602-1607
Weisdorf, Daniel (2016) The role of second transplants for leukemia. Best Pract Res Clin Haematol 29:359-364
He, F; Warlick, E; Miller, J S et al. (2016) Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD. Bone Marrow Transplant 51:1107-12

Showing the most recent 10 out of 89 publications